Patients with lung cancer that carry EML4-ALK fusion respond to tyrosine kinase inhibitors (TKI), such as crizotinib, and therefore unambiguous detection of ALK status in a lung cancer specimen is critical for a treatment decision and predicts the outcome of the affected patient. Here, EML4 is linked to lung carcinoma.